Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAICS | P22234 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579495 | 0.83 | MAOB (0.48) | HDAC2HDAC1HDAC3ROCK2ROCK1 | |
| SCHEMBL4581195 | 0.82 | HDAC1 (0.53) | HDAC2HDAC1HDAC3ROCK2ROCK1 | |
| SCHEMBL4579321 | 0.77 | HDAC2 (0.54) | HDAC2HDAC1HDAC3CYP1A2CYP2C18 | |
| SCHEMBL4580386 | 0.77 | HDAC2 (0.65) | HDAC2HDAC1HDAC3 | |
| SCHEMBL3660004 | 0.75 | HDAC1 (0.59) | CYP2D6HDAC2HDAC1HDAC3 | |
| SCHEMBL4579712 | 0.73 | HDAC1 (0.55) | HDAC2HDAC1HDAC3CYP1A2 | |
| SCHEMBL4579934 | 0.73 | HDAC1 (0.51) | HDAC2HDAC1HDAC3CYP1A2 | |
| SCHEMBL4579784 | 0.72 | HDAC2 (0.50) | HDAC2HDAC1HDAC3CYP1A2CYP2C18 | |
| SCHEMBL8229221 | 0.72 | MAOB (0.43) | ROCK2ROCK1CYP1A2 | |
| SCHEMBL4581147 | 0.72 | HDAC1 (0.66) | CYP2D6HDAC2HDAC1HDAC3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| EP-2007720-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2008-12-31 | — | — | EP | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | PAICS 3574/4885CYP2D6 4762/4885HDAC2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.